FLT3 and acute myeloid leukemia: Importantly, in Idh2R140QFlt3ITD mutant AML combination therapy with FLT3 inhibitor AC220 (quizartinib), significantly decreased mutant cell burden and led to the recovery of normal hematopoiesis from non-mutant stem/progenitor cells[48].